International Journal of Advanced Research in Pharmacy and Education
Volume 5, Print Issue 1 - 2023, Pg. No. 4-6
Peer Reviewed Journal

Review Article

Emerging Trends in Antibiotic Discovery

Rashi Jha[1], Yashi Sharma[2], Mehar Singh[3]

Student, Assistant Professor, MCP Nilanga - Maharashtra College of Pharmacy, Nilanga.

I N F O

Corresponding Author:
Rashi jha, MCP Nilanga - Maharashtra College of Pharmacy, Nilanga.
E-mail Id:
rashijha100@gmail.com
How to cite this article:
Jha R, Sharma Y, Singh M. Emerging Trends in Antibiotic Discovery. *Int J Adv Res Pharm Edu* 2023; 5(1): 4-6.

Date of Submission: 2023-03-05
Date of Acceptance: 2023-03-30

A B S T R A C T

The continuous rise of antibiotic-resistant bacterial strains has prompted the need for innovative approaches to antibiotic discovery. This review article highlights the recent trends and advancements in the field of antibiotic discovery, focusing on novel strategies, technologies, compounds that show promise in overcoming the challenges posed by antibiotic resistance. The article also discusses the potential implications of these emerging trends in shaping the future of antibiotic research and therapeutic development.

Keywords: Antibiotic-Resistant, Novel Strategies, Microbiome, Antibiotic

Introduction

Antibiotics have played a pivotal role in modern medicine by effectively treating bacterial infections. However, the rapid emergence of antibiotic-resistant bacteria has rendered many traditional antibiotics ineffective. This crisis demands a reevaluation of conventional antibiotic discovery methods and the exploration of new avenues to combat antibiotic resistance.

Targeting Novel Bacterial Pathways as Emerging Trends in Antibiotic Discovery

One of the pivotal strategies in combating the escalating challenge of antibiotic resistance lies in the identification and exploration of novel bacterial pathways as potential targets for therapeutic intervention. This approach marks an emerging trend in antibiotic discovery that aims to expand the repertoire of drug targets beyond traditional mechanisms.[1]

Conventional antibiotics predominantly focus on disrupting essential cellular processes like cell wall synthesis, protein synthesis, DNA replication. However, the increasing prevalence of multidrug-resistant strains has underscored the need for alternative strategies. Targeting novel bacterial pathways involves identifying and disrupting key processes that are crucial for the pathogen's virulence or survival but are not commonly exploited by existing antibiotics. Recent research has illuminated various such pathways that hold promise as novel drug targets. These pathways include bacterial virulence factors and quorum sensing systems, which govern intercellular communication among bacteria. By interfering with these processes, researchers aim to attenuate the pathogen's ability to cause disease while minimizing the selection pressure for resistance development.[2]

While the concept of targeting novel pathways is compelling, challenges such as specificity, off-target effects, potential impacts on the host's microbiota must be carefully considered. Nonetheless, this approach presents a significant advancement in the field of antibiotic discovery, offering the potential to revolutionize the way we combat bacterial infections and mitigate the growing threat of antibiotic resistance.[3]

Synthetic Biology and Gene Editing as Emerging Trends in Antibiotic Discovery

In the pursuit of innovative solutions to combat antibiotic resistance, synthetic biology and gene editing have emerged as powerful tools, redefining the landscape of antibiotic discovery. These techniques offer the potential to engineer bacteria to produce novel antibiotics or modify existing ones, providing a fresh perspective on addressing the challenge of drug-resistant pathogens.

Synthetic biology involves the design and construction of biological systems for specific purposes, often harnessing the genetic information and pathways present in microorganisms. With the advent of CRISPR-Cas9 technology, gene editing has become a transformative force, enabling precise modifications in bacterial genomes.[4] This capability has been leveraged to enhance antibiotic production by optimizing biosynthetic pathways, thereby potentially increasing the yield and potency of antimicrobial compounds.

Furthermore, synthetic biology enables the creation of entirely new antibiotics through the engineering of microbial hosts. By introducing foreign genes or altering native genes, researchers can manipulate the production of antimicrobial molecules with enhanced effectiveness against resistant strains. This approach holds the promise of developing tailored antibiotics designed to combat specific pathogens, minimizing collateral damage to beneficial microbiota.[5]

Repurposing Existing Compounds as Emerging Trends in Antibiotic Discovery

As the prevalence of antibiotic-resistant bacteria continues to rise, the repurposing of existing compounds has emerged as a promising strategy in the quest for novel antibiotics. This approach, which involves identifying new therapeutic uses for drugs originally designed for different purposes, offers a streamlined and resource-efficient pathway to address the urgent need for effective antimicrobial agents.[3]

The strategy of repurposing existing compounds capitalizes on the wealth of pharmacological knowledge surrounding approved drugs. By screening libraries of known compounds, researchers can identify molecules with unanticipated antimicrobial properties. These compounds might interact with bacterial targets in novel ways, offering a potential solution to combat drug-resistant pathogens.[6]

One significant advantage of repurposing is the shortened timeline for development. Since the safety profiles of repurposed drugs are already established, the regulatory pathway for their use as antibiotics may be expedited. This accelerated process can potentially bring new treatments to the clinic more rapidly than traditional drug discovery approaches.

Moreover, repurposing has the potential to yield antibiotics with diverse mechanisms of action, which could mitigate the risk of resistance emerging. By exploiting compounds that have proven effective against other diseases, researchers can tap into a reservoir of drug candidates that might otherwise remain overlooked.[7]

Natural Products and Microbiome Exploration as Emerging Trends in Antibiotic Discovery

In the ongoing battle against antibiotic resistance, the exploration of natural products and the intricate world of the human microbiome has emerged as a promising frontier in antibiotic discovery. This innovative approach capitalizes on the vast diversity of microorganisms and their products, fostering the potential for uncovering novel antibiotics and therapeutic strategies.

Natural products have historically been a rich source of antibiotics, giving rise to some of the most effective treatments. Recent advances in genomic and metagenomic techniques have revitalized the search for these compounds by enabling the discovery of unculturable microorganisms and their biosynthetic pathways. These microorganisms, often residing in unique and extreme environments, may produce previously unknown antibiotics with distinct modes of action.[8]

Furthermore, the human microbiome, comprising a diverse array of microorganisms living symbiotically within us, presents an untapped reservoir of potential antibiotic producers. By studying the interactions within the microbiome and understanding the mechanisms by which microorganisms compete and cooperate, researchers can uncover strategies to harness the microbiome's antimicrobial potential against pathogenic invaders.[9-11]

Combination Therapies and Drug Synergy as Emerging Trends in Antibiotic Discovery

In the face of mounting antibiotic resistance, the concept of combination therapies and drug synergy has emerged as a compelling strategy to overcome the limitations of single antibiotics and extend the effectiveness of existing treatments. This innovative approach involves the concurrent use of multiple drugs to enhance their collective efficacy and counteract the development of resistance.

Traditionally, antibiotics have been administered as single agents to target specific bacterial vulnerabilities. However, the adaptive nature of bacteria has led to the rapid emergence of resistance mechanisms against individual drugs. Combination therapies offer a solution by attacking multiple bacterial pathways simultaneously, reducing the likelihood of resistance development and increasing treatment success.[12]

Drug synergy, a cornerstone of combination therapy, occurs when the combined effect of two or more drugs is greater than the sum of their individual effects. This phenomenon can lead to increased bactericidal activity, improved penetration into bacterial biofilms, enhanced host immune response, ultimately resulting in more effective and durable treatments.

Several successful combinations have already demonstrated their potential in clinical practice, such as the use of β-lactam antibiotics with β-lactamase inhibitors and the combination of antibiotics with adjuvant compounds that modulate bacterial virulence or disrupt biofilm formation. Moreover, repurposing non-antibiotic drugs to enhance antibiotic activity has opened new avenues for combination therapies.[8]

Despite its promise, combination therapy faces challenges in terms of optimizing dosing regimens, preventing drug interactions, avoiding potential adverse effects. Additionally, designing effective combinations requires a deep understanding of bacterial biology and the mechanisms underlying drug synergy.[13-14]

Discussion

The emergence of multidrug-resistant bacterial strains underscores the urgency of finding innovative solutions to the antibiotic crisis. The trends discussed in this review offer promising avenues for antibiotic discovery, each with its own strengths and challenges. However, several considerations must be addressed:

Regulatory Hurdles: The approval process for new antibiotics is complex and time-consuming. Regulatory agencies need to adapt to accommodate the unique features of emerging antibiotic discovery methods.

Resistance Surveillance: As new antibiotics are developed, ongoing surveillance is crucial to monitor the emergence of resistance and guide the appropriate use of these drugs. Collaboration and Funding: Antibiotic discovery requires multidisciplinary collaboration and sustained funding to translate promising research into clinically viable therapies.

Conclusion

The current landscape of antibiotic resistance demands a paradigm shift in antibiotic discovery. Emerging trends, including targeting novel bacterial pathways, harnessing synthetic biology, repurposing existing compounds, exploring natural products, developing combination therapies, offer hope in the fight against antibiotic-resistant infections. To ensure the success of these approaches, it is essential to address challenges related to regulation, surveillance, collaboration. By embracing these trends and fostering innovation, the field of antibiotic discovery can pave the way for a more resilient arsenal of antibiotics to safeguard public health.

References

1. Davies, Julian, Dorothy Davies. “Origins and Evolution of Antibiotic Resistance.” Microbiology and Molecular Biology Reviews 74, no. 3 (2010): 417-433.
2. Clatworthy, Anne E., Emily Pierson, Deborah T. Hung. “Targeting Virulence: A New Paradigm for Antimicrobial Therapy.” Nature Chemical Biology 3, no. 9 (2007): 541-548.
3. Rutherford, Steven T., Bonnie L. Bassler. “Bacterial Quorum Sensing: Its Role in Virulence and Possibilities for Its Control.” Cold Spring Harbor Perspectives in Medicine 2, no. 11 (2012): a012427.
4. Moussouni, Malika, Salima Zlitni, Caroline Aubry, et al. “Synthetic Biology for Designing Antibiotics via In Vitro Combinatorial Biosynthesis.” Current Opinion in Microbiology 45 (2018): 115-123.
5. Doudna, Jennifer A., Emmanuelle Charpentier. “Genome Editing: The New Frontier of Genome Engineering with CRISPR-Cas9.” Science 346, no. 6213 (2014): 1258096.
6. Thaker, Maulik N., Wenyu Wang, Panagiota Spanogiannopoulos, et al. “Identifying Producers of Antibacterial Compounds by Screening for Antibiotic Resistance.” Nature Biotechnology 31, no. 10 (2013): 922-927.
7. Ling, Losee L., Tingting Schneider, A. John Peoples, et al. “A New Antibiotic Kills Pathogens without Detectable Resistance.” Nature 517, no. 7535 (2015): 455-459.
8. Nicholson, Wayne L. “Roles of Bacillus Endospores in the Environment.” Cell and Molecular Life Sciences 59, no. 3 (2002): 410-416.
9. Berti,rew D., David A. Rasko. “Streptomyces in the Marine Environment: A Genomics Approach to Unraveling the Ecology, Physiology, Metagenomics of Marine-Derived Actinobacteria.” Frontiers in Microbiology 9 (2018): 2541.
10. Forsberg, Kevin J., Sandeep Patel, Timothy A. Wencewicz, Gautam Dantas. “The Tetracycline Destructases: A Novel Family of Tetracycline-Inactivating Enzymes.” ChemBioChem 16, no. 11 (2015): 1573-1580.
11. Lewis, Kim. “Platforms for Antibiotic Discovery.” Nature Reviews Drug Discovery 12, no. 5 (2013): 371-387.
12. Mulani, Murtuza S., Eisha E. Kamble, Surbhi N. Kumkar, Mubin S. Tawre, Kashinath R. Pardesi. “Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.” Frontiers in Microbiology 10 (2019): 539.
13. Spellberg, Brad, John G. Bartlett, David N. Gilbert. “The Future of Antibiotics and Resistance.” New England Journal of Medicine 368, no. 4 (2013): 299-302.
14. World Health Organization. “Global Action Plan on Antimicrobial Resistance.” 2015. Accessed August 27, 2023. https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/.